An experimental gene-editing therapy developed by Crispr Therapeutics is showing promise for treating heart disease.

ALX Oncology Holdings Inc (ALXO) reports strong efficacy in clinical trials and maintains a robust cash position, paving the ...

Q3 2025 Earnings Call Transcript November 7, 2025 Fulgent Genetics, Inc. beats earnings expectations. Reported EPS is ...

Fulgent Genetics (($FLGT)) has held its Q3 earnings call. Read on for the main highlights of the call. Fulgent Genetics’ recent earnings call ...